DICE Therapeutics, Inc.

NasdaqGM:DICE Stock Report

Market Cap: US$2.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

DICE Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

J. Judice

Chief executive officer

US$5.8m

Total compensation

CEO salary percentage9.4%
CEO tenure10yrs
CEO ownership1.7%
Management average tenure2.6yrs
Board average tenure2.7yrs

Recent management updates

Recent updates

We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

May 14
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

Oct 11

Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

Sep 11
Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

DICE Therapeutics GAAP EPS of -$0.58

Aug 11

DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs

Jul 18

CEO Compensation Analysis

How has J. Judice's remuneration changed compared to DICE Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$104m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$6mUS$540k

-US$84m

Sep 30 2022n/an/a

-US$77m

Jun 30 2022n/an/a

-US$74m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$6mUS$465k

-US$49m

Sep 30 2021n/an/a

-US$40m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020US$637kUS$437k

-US$24m

Compensation vs Market: J.'s total compensation ($USD5.77M) is about average for companies of similar size in the US market ($USD5.11M).

Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.


CEO

J. Judice (59 yo)

10yrs

Tenure

US$5,773,577

Compensation

Dr. J. Kevin Judice, Ph D., founded DiCE Molecules SV, Inc. (formerly known as DiCE Molecules Corp). and serves as its Chief Executive Officer, President and Secretary. Dr. Judice has extensive experience...


Leadership Team

NamePositionTenureCompensationOwnership
J. Judice
Founder10yrsUS$5.77m1.67%
$ 38.0m
Scott Robertson
Chief Business & Financial Officer5.7yrsUS$2.67m0.41%
$ 9.4m
Timothy Lu
Chief Medical Officer3yrsUS$2.72m0.32%
$ 7.2m
John Jacobsen
Chief Scientific Officer2.2yrsUS$714.79k0.31%
$ 7.0m
Mary Riley
General Counsel1.4yrsno datano data
Venkat Thalladi
Senior Vice President of CMC2.2yrsno datano data
Paul Fatheree
Senior Vice President of Medicinal Chemistryno datano datano data

2.6yrs

Average Tenure

54yo

Average Age

Experienced Management: DICE's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
J. Judice
Founderno dataUS$5.77m1.67%
$ 38.0m
Sharon Tetlow
Independent Director2.8yrsUS$264.90k0.10%
$ 2.4m
Richard Scheller
Independent Chairman of the Board7.7yrsUS$371.88k0.018%
$ 400.6k
James Scopa
Independent Director2.8yrsUS$264.90k0.086%
$ 1.9m
Mittie Doyle
Independent Director1.4yrsUS$552.51k0%
$ 0
Jake Simson
Independent Director2.7yrsUS$231.45kno data
Lisa Bowers
Independent Director1.4yrsUS$552.51k0%
$ 0

2.7yrs

Average Tenure

59yo

Average Age

Experienced Board: DICE's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.